One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
A novel long-acting local anesthetic – HTX-011 (ZYNRELEF™) for postoperative pain control
Ramanjot S Kang, Zhaosheng Jin & Tong J Gan
doi : 10.1080/17512433.2022.2132227
Expert Review of Clinical Pharmacology, Volume 15, Issue 10 (2022)
Pain following most surgical procedures is expected. However, the treatment and management of postoperative surgical pain have remained challenging. The use of opioid therapy has become increasingly controversial given the limited therapeutic window of these drugs, the adverse side effects, and the potential for abuse.
Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency
M. P. H. van den Broek, Marjon V. Verschueren & C. A. J. Knibbe
doi : 10.1080/17512433.2022.2132228
Several guidelines advise to monitor therapeutic LMWH therapy with peak anti-Xa concentrations in renal insufficiency with subsequent dose adjustments. A better understanding of the clinical association between peak anti-Xa concentrations and clinical outcomes is mandatory, because misunderstanding this association could lead to erroneous, and potentially even harmful, LMWH dose adjustments
Recent advances in the treatment of childhood asthma: a clinical pharmacology perspective
Amir Hossein Alizadeh Bahmani, Mahmoud I. Abdel-Aziz, Anke H. Maitland- van der Zee & Susanne J.H. Vijverberg
doi : 10.1080/17512433.2022.2131537
Childhood asthma is a complex heterogenous inflammatory disease that can pose a large burden on patients and their caregivers. There is a strong need to adapt asthma treatment to the individual patient taking into account underlying inflammatory profiles, moving from a ‘one size fits all’ approach toward a much-needed personalized approach.
Clinical pharmacology of antiplatelet drugs
Georg Gelbenegger & Bernd Jilma
doi : 10.1080/17512433.2022.2121702
Platelets play a key role in arterial thrombosis and antiplatelet therapy is pivotal in the treatment of cardiovascular disease. Current antiplatelet drugs target different pathways of platelet activation and show specific pharmacodynamic and pharmacokinetic characteristics, implicating clinically relevant drug–drug interactions.
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Amir Abbas Momtazi-Borojeni, Maciej Banach, Massimiliano Ruscica & Amirhossein Sahebkar
doi : 10.1080/17512433.2022.2132229
There are inconsistent findings regarding the effect of lipid-lowering agents on nonalcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is an important player in cholesterol homeostasis and intracellular lipogenesis, and PCSK9 inhibitors (PCSK9-i) have been found to be efficient for pharmacological management of hyperlipidemia.
Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology
Caterina Lanna, Sara Lambiase, Ruslana Gaeta Shumak, Cristiana Borselli, Terenzio Cosio, Annunziata Dattola, Luca Bianchi & Elena Campione
doi : 10.1080/17512433.2022.2130758
Psoriasis is an inflammatory, chronic and immune-mediated disease that can affect the skin and joints. Pro-inflammatory cytokines have a dominant role in the pathogenesis of this heterogeneous disease in which the IL-23/IL-17 axis plays a crucial role. The IL-17 family is involved in numerous processes such as immune defense, intestinal disorders and diseases of the central nervous system.
Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19
Rosanna Ruggiero, Nunzia Balzano, Raffaella Di Napoli, Maria Giuseppa Sullo, Francesco Rossi, Annalisa Capuano & Concetta Rafaniello
doi : 10.1080/17512433.2022.2132226
Drug repurposing represented an important contribution in the management of COVID-19, becoming the first line of defense to mitigate the effects of the new coronavirus. In a brief time, drug repurposing (DR) provided potentially effective and already available drugs for COVID-19, while specific therapies against SARS-CoV-2 and/or vaccines were developing. Identifying repurposed drugs requires a multidisciplinary approach, where clinical pharmacology represents the missing piece of the puzzle.
The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis
Boyang Zhou, Jialin Dong, Surong Liang, Shuai Shang & Linfeng Li
doi : 10.1080/17512433.2022.2120469
Dupilumab is approved for multiple type 2 inflammatory diseases. In the treatment procedure, the changes of IgE levels need further analysis. We evaluated the changes of IgE levels through meta-analysis, aiming to provide a more comprehensive result.
BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study
Raffaele Pellegrino, Gianluca Pellino, Lucio Selvaggi, Francesco Selvaggi, Alessandro Federico, Marco Romano & Antonietta Gerarda Gravina
doi : 10.1080/17512433.2022.2120466
Patients with inflammatory bowel disease were excluded from trials that led to the approval of anti-COVID-19 vaccines and are worthy of real-life studies providing information on the safety of these vaccines in this clinical setting.
Management guideline for the off-label use of medicine in China (2021)
Wei Zuo, Yajia Sun, Rongji Liu, Liping Du, Nan Yang, Wenjuan Sun, Ping Wang, Xiaowan Tang, Yunlan Liu, Yuanyuan Ma, Min Meng, Ruobing Lei, Xuelian Yan, Hua Peng, Qing Chang, Hui Pan, Bo Zhang, Yaolong Chen & Shuyang Zhangon behalf of the guideline working group
doi : 10.1080/17512433.2022.2120468
Off-label drug use embodies a thorough clinical diagnosis and evaluation of treatment needs and should not be confused with unreasonable drug use, but it also faces potential risks with drug safety and legal issues.
